A clinical screening algorithm for primary hyperoxaluria type 1 in adults on dialysis.

Authors:
Ferraro PM; D'Ambrosio V; Gambaro G; Giachino D; Groothoff J and 1 more

Journal:
Nephrol Dial Transplant

Publication Year: 2024

DOI:
10.1093/ndt/gfad184

PMCID:
PMC10828199

PMID:
37708050

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Nephrol Dial Transplant

Abbreviation: Nephrol Dial Transplant

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Transplantation

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A nomogram predicting the histologic activity of lupus nephritis from clinical parameters.
Gao C; Bian X; Wu L and 6 more (2024) - Transparency Score: 3/6
Associations of neutral pH, low-GDP peritoneal dialysis solutions with patient survival, transfer t…
Chen JHC; Johnson DW; Cho Y and 8 more (2024) - Transparency Score: 3/6
Binding and detoxification efficiency of albumin decline after haemodialysis.
Boss K; Waterstradt K; Schnurr K and 7 more (2024) - Transparency Score: 3/6
Contrast-enhanced ultrasonography reveals a lower cortical perfusion and a decreased renal flow res…
Damianaki A; Hendriks-Balk M; Brito W and 7 more (2024) - Transparency Score: 3/6
COVID-19 and cardiovascular disease in patients with chronic kidney disease.
Del Vecchio L; Balafa O; Dounousi E and 7 more (2024) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"CONFLICT OF INTEREST STATEMENT P.M.F. received consultant fees and grant/other support from Allena Pharmaceuticals, Alnylam, Amgen, AstraZeneca, Bayer, BioHealth Italia, Gilead, Otsuka Pharmaceuticals, Rocchetta and Vifor Fresenius, and royalties as an author for UpToDate. V.D’A. received consultant fees from Allena Pharmaceuticals. G.M. received consultant fees and grant/other support from Alnylam and Novo Nordisk. All other authors report no disclosures."

Evidence found in paper:

"FUNDING The paper was not funded."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025